Video

Findings help investigators understand how FDA-approved AGN-19058 behaves

Author(s):

Kassi Jackson
Conferences|ASCRS

George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.

Related Videos
Related Content
Study: Fluoxetine improves visual acuity in adults with amblyopia
December 11th 2024

Study: Fluoxetine improves visual acuity in adults with amblyopia

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

CORXEL and LENZ Therapeutics announce positive topline data from phase 3 presbyopia trial of LNZ100 in China
October 29th 2024

CORXEL and LENZ Therapeutics announce positive topline data from phase 3 presbyopia trial of LNZ100 in China

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD

© 2024 MJH Life Sciences

All rights reserved.